Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 29,000 shares, an increase of 90.8% from the October 15th total of 15,200 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average trading volume of 21,900 shares, the days-to-cover ratio is presently 1.3 days.

Aprea Therapeutics Trading Down 2.6 %

Shares of APRE opened at $3.43 on Wednesday. Aprea Therapeutics has a 12-month low of $2.15 and a 12-month high of $8.85. The company has a market capitalization of $18.62 million, a PE ratio of -1.25 and a beta of 0.97. The business’s 50 day moving average is $3.34 and its 200 day moving average is $3.94.

Aprea Therapeutics (NASDAQ:APRE) last issued its earnings results on Thursday, November 7th. The company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.11. The firm had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.45 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 56.72%. Equities research analysts predict that Aprea Therapeutics will post -2.74 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on APRE shares. Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Aprea Therapeutics in a research note on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Aprea Therapeutics in a research note on Thursday, October 24th.

Insider Activity at Aprea Therapeutics

In other news, Director Marc Duey bought 30,000 shares of the company’s stock in a transaction on Wednesday, October 16th. The shares were acquired at an average cost of $4.39 per share, with a total value of $131,700.00. Following the completion of the transaction, the director now owns 240,113 shares of the company’s stock, valued at approximately $1,054,096.07. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Aprea Therapeutics news, Director Marc Duey purchased 30,000 shares of the company’s stock in a transaction dated Wednesday, October 16th. The shares were acquired at an average price of $4.39 per share, for a total transaction of $131,700.00. Following the purchase, the director now directly owns 240,113 shares of the company’s stock, valued at $1,054,096.07. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bernd R. Seizinger acquired 10,000 shares of Aprea Therapeutics stock in a transaction dated Friday, October 11th. The stock was bought at an average price of $2.68 per share, with a total value of $26,800.00. Following the completion of the purchase, the director now directly owns 44,730 shares in the company, valued at $119,876.40. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 42,290 shares of company stock worth $165,096. 12.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Stonepine Capital Management LLC purchased a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics makes up 0.5% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st largest position. Stonepine Capital Management LLC owned approximately 2.53% of Aprea Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.